文献速递心境障碍

多次阴性试验后药物疗效评估:吉哌隆的FDA审批历程

Assessing Drug Efficacy After Multiple Negative Trials-Gepirone's Journey Through the FDA.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

本文回顾吉哌隆缓释片(ER)用于重性抑郁障碍的审批案例。FDA基于13项试验评估疗效,仅2项急性治疗试验为阳性,其余未显示优于安慰剂,3项显示对活性对照药统计学劣效。FDA四次拒绝新药申请,但最终在2015年批准,引发对监管灵活性和产品标签透明度的讨论。

要点

  • FDA评估吉哌隆ER的13项试验中仅2项急性治疗试验阳性,其余多数未显示优于安慰剂。
  • FDA曾四次拒绝新药申请,顾问委员会投票认为疗效未证实,但最终仍批准。
  • 作者建议产品标签应透明报告所有充分且良好对照试验,而不仅是阳性结果。

核心结论

  • 吉哌隆案例显示FDA在证据冲突时行使监管灵活性,聚焦少数试验的统计学显著性而非临床显著性,可能批准获益有限的药物。

研究设计与样本

  • 本文为案例回顾,审查吉哌隆缓释片(ER)用于重性抑郁障碍的FDA审批过程,涉及13项试验(12项急性治疗试验和1项维持或复发预防试验)。

主要发现

  • FDA判定2项急性治疗试验为阳性;在其他试验中吉哌隆ER未显示优于安慰剂,3项试验显示对活性对照药统计学劣效。
  • FDA因担心阳性试验可能偶然及存在大量相反证据,四次拒绝新药申请(1999、2002、2004年Organon,2007年Fabre-Kramer Pharmaceuticals, Inc)。
  • 2015年FDA顾问委员会投票认为药物疗效未证实,但FDA领导层最终同意申办方论点,认为2项阳性试验非偶然且满足法定疗效标准,批准该药。

关键数值与推荐

  • FDA基于13项试验评估吉哌隆ER疗效,其中2项急性治疗试验被判定为阳性。
  • FDA四次拒绝新药申请,2015年顾问委员会投票认为疗效未证实,但最终批准。

临床怎么用

  • 临床医生应知晓FDA批准可能基于少数阳性试验,处方时应参考产品标签中所有充分且良好对照试验的透明报告。

局限性

  • 本文为单一药物案例回顾,未系统评估其他药物或监管政策的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Surveys have indicated that patients and clinicians can overestimate the efficacy and safety of drugs approved by the US Food and Drug Administration (FDA). In recent years, only approximately half of new drug approvals have been based on 2 or more adequate and well-controlled trials; furthermore, regulations do not limit how many trials can be conducted or provide clear guidance on how the FDA should consider a drug with conflicting evidence of benefit from multiple trials. OBJECTIVE: To understand how the FDA evaluated a single investigational drug with positive and negative preapproval trials. FINDINGS: The case of gepirone extended release (ER), approved for major depressive disorder, was reviewed. The FDA based its efficacy evaluation of gepirone ER on 13 trials: 12 acute treatment trials and 1 maintenance or relapse prevention trial. The FDA judged 2 acute treatment trials as positive. In the others, gepirone ER did not demonstrate superiority to placebo; and for 3, the FDA found evidence of statistical inferiority to an active comparator. Concerned that the positive trials might have occurred by chance and the amount of countervailing evidence, the FDA rejected the New Drug Application from the sponsor 4 times (Organon in 1999, 2002, and 2004, and Fabre-Kramer Pharmaceuticals, Inc in 2007). In 2014, the sponsor filed a dispute resolution request, leading to intervention by senior FDA leaders. In 2015, an FDA Advisory Committee voted that drug efficacy had not been demonstrated. Nevertheless, FDA leaders came to agree with the sponsor's arguments that the 2 positive trials had not occurred by chance and that the drug satisfied the FDA statutory standard for efficacy, and the drug was approved. CONCLUSIONS AND RELEVANCE: The case of gepirone shows how the FDA evaluated an investigational drug with conflicting evidence. The FDA sometimes exercises "regulatory flexibility" and focuses on statistical (as opposed to clinical) significance in a few trials, allowing the approval of drugs with scant benefits. Product labeling should transparently report on all adequate and well-controlled trials relating to an FDA-approved indication, not just those with positive outcomes, so that clinicians can make better-informed prescribing decisions.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Turner EH, Powers JH, Ahn-Horst RY, et al. Assessing Drug Efficacy After Multiple Negative Trials-Gepirone's Journey Through the FDA. JAMA Psychiatry. 2026. PMID: 42340691. doi:10.1001/jamapsychiatry.2026.1438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。